Skip to main content

Table 2 Treatment regimens and antiviral response

From: Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Regimen All patients (N = 147) Patients who were evaluated for SVR (N = 132) Patients with treatment discontinuation or loss to follow-up (N = 15) Virologic responses
RVR (N = 109) SVR (N = 132)
Rate (%) 95% CI of %* Rate (%) 95% CI of %*
SOF/LDV 12 W 32 (21.8%) 30 (22.7%) 2 (13.3%) 15/16 (93.8%) 69.8–99.8% 30/30 (100%) 88.4–100%
SOF/LDV 24 W 9 (6.1%) 7 (5.3%) 2 (13.3%) 9/9 (100%) 66.4–100% 7/7 (100%) 59.0–100%
SOF/LDV + RBV 12 W 46 (31.3%) 42 (31.8%) 4 (26.6%) 39/41 (95.1%) 83.5–99.4% 42/42 (100%) 91.6–100%
SOF/LDV + RBV 24 W 7 (4.8%) 6 (4.5%) 1 (6.7%) 3/6 (50%) 11.8–88.2% 6/6 (100%) 54.1–100%
SOF/DCV 12 W 22 (15%) 20 (15.1%) 2 (13.3%) 14/14 (100%) 76.9–100% 20/20 (100%) 83.2–100%
SOF/DCV 24 W 4 (2.7%) 3 (2.3%) 1 (6.7%) 2/2 (100%) 15.8–100% 3/3 (100%) 29.2–100%
SOF/DCV + RBV 12 W 5 (3.4%) 4 (3.1%) 1 (6.7%) 3/3 (100%) 29.2–100% 4/4 (100%) 39.8–100%
SOF/DCV + RBV 24 W 13 (8.8%) 12 (9.1%) 1 (6.7%) 13/13 (100%) 75.3–100% 12/12 (100%) 73.5–100%
SOF/VEL 12 W 7 (4.7%) 7 (5.3%) 0 (0%) 4/4 (100%) 39.8–100% 7/7 (100%) 59.0–100%
SOF/VEL 24 W 1 (0.7%) 0 (0%) 1 (6.7%) NA NA NA NA
SOF + RBV 24 W 1 (0.7%) 1 (0.8%) 0 (0%) 1/1 (100%) 2.5–100% 1/1 (100%) 2.5–100%
Total 147 (100%) 132 (100%) 15 (100%) 103/109 (94.5%) 88.4–98.0% 132/132 (100%) 97.2–100%
  1. SOF sofosbuvir, LDV ledipasvir, DCV daclatasvir, VEL velpatasvir, RBV ribavirin, W weeks, RVR rapid virologic response, SVR sustained virologic response, NA not available, CI confidence interval, N number
  2. *Binomial exact calculation